Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears BioMerieux's Sepsis-Risk Dx as an IVD

NEW YORK (GenomeWeb News) — BioMérieux said today the US Food and Drug Administration has cleared its in vitro diagnostic that tests for a patient’s risk of developing severe sepsis and septic shock.
 
The company said its VIDAS B.R.A.H.M.S. PCT assay is designed to help assess the risk that a critically ill patient with a bacterial infection faces of developing severe sepsis or septic shock.
 
BioMérieux launched the assay in Europe earlier this year.
 
The test, which measures procalcitonin, a biomarker for bacterial infections, is to be administered on a patient’s first day of admittance into the intensive care unit and takes around 20 minutes to produce results, BioMérieux said.
 
“As the progression of severe bacterial infections is affected by how early the patient receives appropriate treatment, measuring PCT levels is valuable in ICUs where sepsis represents a major health challenge,” the company said in a statement.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.